| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
(S)-Coriolic acid (25μM) damages bronchial epithelium and modifies the structure of mitochondria[2].
(S)-Coriolic acid (30 nM; 6 hours; keratinocytes with or without E-FABP) activates NF-κB to cause K1 expression. Inducing IκB degradation and activating NF-κB, (S)-Coriolic acid raises the phosphorylation of IκBαat serine 32. The phosphorylation of Ikkinase-bat tyrosine 199 is also increased by (S)-Coriolic acid, and this subsequently promotes the phosphorylation of IκBα and NF-kB activation[3]. |
|---|---|
| ln Vivo |
(S)-Coriolic acid (0-0.6 mg per mouse; Intranasally once a day for 3 consecutive days) causes epithelial damage, mitochondrial dysfunction, severe airway dysfunction, and airway neutrophilia[2].
|
| Animal Protocol |
BALB/c mice (6-8 weeks)[2]
0-0.6 mg per mouse Intranasally once a day for 3 consecutive days |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
13-hydroxyoctadecadienoic acid has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoyl]oxyoxane-2-carboxylic acid and (2S,3S,4S,5R)-6-[(6S,7E,9Z)-17-carboxyheptadeca-7,9-dien-6-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid. |
| References |
|
| Additional Infomation |
13(S)-HODE is an HODE (hydroxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroxy group is at position 13 (with S-configuration). It has a role as a mouse metabolite, a human xenobiotic metabolite and an antineoplastic agent. It is a conjugate acid of a 13(S)-HODE(1-).
(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid has been reported in Lithothamnion corallioides, Pleurotus pulmonarius, and other organisms with data available. 13-Hydroxyoctadecadienoic Acid is a monohydroxy fatty acid resulting from the oxidation of linoleic acid or 13-hydroperoxy-9,11-octadecadienoic acid (13-HpODE). 13-HODE may mediate physiological and pathological responses and is a potential biomarker of various human diseases, and could contribute to the progression of certain diseases. |
| Molecular Formula |
C18H32O3
|
|---|---|
| Molecular Weight |
296.44488
|
| Exact Mass |
296.235
|
| Elemental Analysis |
C, 72.93; H, 10.88; O, 16.19
|
| CAS # |
29623-28-7
|
| Related CAS # |
198123-90-9 (ethanolamide); 29623-28-7
|
| PubChem CID |
6443013
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
422.7±20.0 °C at 760 mmHg
|
| Flash Point |
223.6±18.3 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.492
|
| LogP |
5.32
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
21
|
| Complexity |
295
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCC[C@@H](/C=C/C=C\CCCCCCCC(=O)O)O
|
| InChi Key |
HNICUWMFWZBIFP-IRQZEAMPSA-N
|
| InChi Code |
InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1
|
| Chemical Name |
(9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
|
| Synonyms |
13S-Hydroxy-9Z,11E-octadecadienoic acid; 13(S)HODE
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3734 mL | 16.8668 mL | 33.7336 mL | |
| 5 mM | 0.6747 mL | 3.3734 mL | 6.7467 mL | |
| 10 mM | 0.3373 mL | 1.6867 mL | 3.3734 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
